GlassScriptPhysician profile
Oksana Levitansky
NPI 1881623445
$1,890.19
in general payments reported to CMS, 2019-2025
15 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $28.42 · 2021: $352 · 2022: $264 · 2023: $620 · 2024: $322 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $482.08 | 2020-2023 | |
| Abbvie INC. | $447.11 | 2021-2025 | |
| Axsome Therapeutics, INC. | $252.59 | 2023-2024 | Auvelity |
| Boston Scientific Corporation | $156.23 | 2023 | Lux-Dx Insertable Cardiac Monitor |
| Integra Lifesciences Corporation | $133.34 | 2023 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Astrazeneca Pharmaceuticals LP | $111.21 | 2020-2025 | Farxiga |
| Allergan, INC. | $54.18 | 2019 | |
| Ardelyx, INC. | $51.92 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $48.95 | 2021-2023 | Trelegy Ellipta |
| Abbott Laboratories | $46.41 | 2025 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $25.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.68 | 2019 | |
| Amgen INC. | $21.78 | 2019 | |
| Aimmune Therapeutics, INC. | $20.51 | 2024 | |
| Horizon Therapeutics Plc | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oksana Levitansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.